South Korea\’s hybrid car sales soared 41% year-on-year in the first four months

Market tracker CarIsYou said on Thursday that hybrid vehicle registrations in South Korea increased 41% year-on-year in the first four months of this year amid a slowdown in pure electric vehicle sales.

Market tracker CarIsYou said on Thursday that hybrid vehicle registrations in South Korea increased 41% year-on-year in the first four months of this year despite a slowdown in pure electric vehicle sales.
CarIsYou said in a report that the number of newly registered gasoline hybrids and plug-in hybrids in South Korea jumped to 129,201 in the first four months of this year from 91,750 in the same period last year.
Ninety-one percent of newly registered hybrid cars were from Hyundai Motor and its smaller subsidiary Kia Motors. Japanese brands – Honda, Toyota and its luxury brand Lexus – accounted for 5.7%. The rest were other brands.
CarIsYou said: Demand for gasoline hybrid models is expected to remain strong for the time being. But in the long term, if governments come up with solutions to high electric vehicle prices and insufficient charging infrastructure, electric vehicle sales will rebound.

Like (0)
Previous May 23, 2024 5:02 pm
Next May 24, 2024 7:39 pm

Related posts

  • British opioid withdrawal drug maker Indivior confirms relocation of primary launch site to New York

    The British drugmaker, which makes opioid addiction treatments Suboxone and Sublocade, said shareholders had expressed support for the move, which would retain London as a secondary listing location for Indivior.

    stock options April 25, 2024
  • Reading the markets through volatility index

    Volatility index or India VIX last week captured traders’ attention when it plunged nearly 20 per cent during intra-day on April 23, to 9.8, even as the process of General Elections to the Lok Sabha just began. However, the index bounced back a little and is currently ruling around 11. The sudden fall caught a lot of traders, who indulge in strategic option strategies such as strangle and straddle, off-guard as the premium dipped sharply. This also signalled that traders are more complacent.

    stock options April 27, 2024
  • Glenmark Pharmaceuticals receives ANDA approval for acetaminophen and ibuprofen tablets

    Glenmark Pharmaceuticals Ltd. has received final approval from the United States Food & Drug Administration (USFDA) for Acetaminophen and Ibuprofen tablets, 250 mg/125 mg (OTC).

    stock options April 29, 2024
  • Microsoft will invest $3.2 billion in Sweden to strengthen AI and cloud service facilities

    Sina Technology News on the afternoon of June 3rd, Beijing time, Microsoft plans to invest US$3.2 billion in artificial intelligence AI and cloud service facilities in Sweden, which is its largest infrastructure investment in the history of this Nordic country.

    stock options June 3, 2024
  • Yifang Biological (688382.SH): Net profit in 2023 -284 million yuan

    Gelonghui April 25丨Yifang Biotech (688382.SH) released its 2023 annual report. During the reporting period, the company made every effort to promote clinical research and cooperative development of major products and made important progress. In 2023, it achieved operating income of 186 million. Yuan, the net profit attributable to shareholders of listed companies was -284 million yuan, a year-on-year loss reduction of 41.26%, and the loss margin narrowed compared with the same period last year, mainly due to the increase in the company\’s technology licensing and technical cooperation income in 2023.

    stock options April 25, 2024
  • Rongzhi Rixin (688768.SH): Net loss in the first quarter was 19.3024 million yuan

    Gelonghui April 25丨Rongzhi Rixin (688768.SH) released the first quarter report of 2024. During the reporting period, the company achieved operating income of 60.7755 million yuan, a year-on-year increase of 6.32%; the net loss attributable to shareholders of the listed company was 1930.24 million; the net loss attributable to shareholders of the listed company after excluding non-recurring gains and losses was 19.4047 million yuan; the basic loss per share was 0.24 yuan/share.

    stock options April 25, 2024